HER-2 Gene Amplification

14 clinical trials · Condition

Record	Firm	Date
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma (NCT05318339)	Chinese Academy of Medical Sciences	2022-03-10
Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients (NCT05170256)	Morten Mau-Sørensen	2022-02-04
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929)	Carisma Therapeutics Inc	2021-02-02
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (NCT04650451)	Bellicum Pharmaceuticals	2020-12-07
Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor (NCT04215159)	Jin-Hee Ahn	2019-12-30
The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor (NCT04179656)	Tianjin Medical University Second Hospital	2019-12-01
Trastuzumab in HER2-positive Biliary Tract Cancer (NCT03613168)	Changhoon Yoo	2019-06-01
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas (NCT03783936)	Ashwin Somasundaram	2019-01-24
Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer (NCT03979911)	University Hospital, Brest	2019-01-22
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 (NCT03630809)	H. Lee Moffitt Cancer Center and Research Institute	2019-01-10
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach (NCT01774851)	Merrimack Pharmaceuticals	2013-01-01
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer (NCT01304784)	Merrimack Pharmaceuticals	2011-01-01

Track HER-2 Gene Amplification automatically

Every clearance here is in the API, with alerts when new ones post.